Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – Here’s What Happened

Structure Therapeutics Inc. (NASDAQ:GPCR) shares gapped up prior to trading on Monday . The stock had previously closed at $15.90, but opened at $18.00. Structure Therapeutics shares last traded at $17.69, with a volume of 145,502 shares trading hands.

Analysts Set New Price Targets

A number of research firms have weighed in on GPCR. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Structure Therapeutics in a research report on Thursday, December 19th. Stifel Nicolaus assumed coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective on the stock. William Blair initiated coverage on Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating for the company. Finally, JMP Securities reissued a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Trading Down 0.3 %

The firm has a market capitalization of $1.08 billion, a PE ratio of -25.54 and a beta of -1.35. The stock has a 50 day simple moving average of $20.52 and a 200 day simple moving average of $28.88.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. As a group, equities analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Institutional Trading of Structure Therapeutics

Large investors have recently modified their holdings of the business. Handelsbanken Fonder AB lifted its holdings in Structure Therapeutics by 130.3% in the 1st quarter. Handelsbanken Fonder AB now owns 380,000 shares of the company’s stock worth $6,578,000 after buying an additional 215,000 shares during the period. GAMMA Investing LLC raised its holdings in shares of Structure Therapeutics by 663.8% during the first quarter. GAMMA Investing LLC now owns 8,776 shares of the company’s stock valued at $152,000 after acquiring an additional 7,627 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Structure Therapeutics in the fourth quarter worth $3,091,000. GF Fund Management CO. LTD. bought a new stake in Structure Therapeutics in the fourth quarter valued at $34,000. Finally, Woodline Partners LP boosted its holdings in Structure Therapeutics by 0.7% in the fourth quarter. Woodline Partners LP now owns 333,901 shares of the company’s stock valued at $9,055,000 after acquiring an additional 2,328 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.